Feb 14, 2014 by Peter StephensThe Major Factors Behind Valeant's DoubleValeant Pharmaceuticals International, Inc. has performed well of late, but can it continue to do so?
Feb 14, 2014 by Peter Stephens2 Health Care Partnerships Go Head-To-HeadWhile the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end
Feb 13, 2014 by Peter StephensCan Pfizer Crush the Market in 2014?Pfizer has cut costs and is now looking ahead to the launch of new products, but can it beat the market in 2014?
Feb 12, 2014 by Peter StephensCan Biogen Idec Crush The Market In 2014?After strong results and positive news, can Biogen Idec outperform the Nasdaq in 2014?
Feb 11, 2014 by Peter Stephens3 Biotech Stocks With Great Potential in 2014These stocks had a great 2013 and may have an even better 2014.
Feb 11, 2014 by Peter StephensFor These 3 Stocks, Recent Weakness Yields Potential OpportunityThese companies reported tough numbers this past quarter. Here's why this may be a great opportunity.
Feb 10, 2014 by Peter Stephens3 Major Health-Care Deals You Need to Know About Forest Laboratories, Inc.'s (NYSE: FRX) purchase of Aptalis is just the latest in a plethora of major health-care deals.
Feb 10, 2014 by Peter StephensA Game-Changer for Gilead Sciences?Recent fourth quarter results from Gilead Sciences, Inc. (NASDAQ: GILD) were upbeat, but are they a game-changer?
Feb 9, 2014 by Peter StephensWhy You Shouldn't Overlook Amgen, Inc.Amgen, Inc.'s (NASDAQ: AMGN) recent results were generally in line with expectations but still should be of major interest to investors.
Feb 9, 2014 by Peter StephensWhy AbbVie's First Year on Its Own Was a SuccessIn its first year as an independent company, AbbVie (NYSE: ABBV) delivered impressive figures and guidance.
Feb 7, 2014 by Peter StephensWhy Wall Street Is Excited about Alexion PharmaceuticalsThe fourth-quarter update from Alexion Pharmaceuticals, Inc. led to upgrades from Wall Street. Here's why.
Feb 7, 2014 by Peter Stephens3 Stocks Poised to Dominate the Market in 2014These companies could have a great 2014. Here's why.
Feb 7, 2014 by Peter StephensThe Effects Of Copycat Drugs on Novartis, Merck, and Eli LillyNovartis, Merck, and Eli Lilly are all being challenged by low-cost generic drugs. How are they coping with the problem?
Feb 2, 2014 by Peter StephensWhat's the Key Driver Behind Pfizer's Share Price?It seems as though restructuring is more important to shareholders of Pfizer (NYSE: PFE) than news flow surrounding its drug pipeline.
Feb 2, 2014 by Peter StephensCan Bristol-Myers Squibb Crush the Market in 2014?Fourth-quarter results were a mixed bag for Bristol-Myers Squibb (NYSE: BMY). Can it perform in 2014?
Feb 2, 2014 by Peter StephensIs It All Doom and Gloom for Eli Lilly & Co.?A tough fourth quarter for Eli Lilly (NYSE: LLY) has left many shareholders feeling downbeat, but is there still hope?
Feb 2, 2014 by Peter Stephens3 Reasons for GlaxoSmithKline to CheerGlaxoSmithKline’s (NYSE: GSK) drug pipeline is showing strength, while Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) look well-placed, too.
Jan 26, 2014 by Peter Stephens3 Reasons to Seek Out More Stable StocksWith markets experiencing a dip on Friday, more stable stocks could be on the agenda.
Jan 26, 2014 by Peter Stephens3 Reasons to Tune In to Health Care in 2014The year has started with key developments for Intuitive Surgical, St Jude Medical, and Edwards Lifesciences.
Jan 26, 2014 by Peter StephensWhy 2014 Could Be a Huge Year for M&A ActivityWith 2014 less than a month old, there have been several major deals already. However, there could be more to come.
